AIMS: The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas. METHODS AND RESULTS: Two thousand one hundred and four peripheral lymphomas of various types were immunostained with a monoclonal antibody against immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), which recognizes the equivalents of MZ in human lymphoid tissues other than spleen. IRTA1 expression was restricted to extranodal (93%) and nodal MZLs (73%) and to lymphomas with MZ differentiation. Extranodal MZL cells with the strongest IRTA1 expression were usually located adjacent to epithelia, mimicking the IRTA1 expression pattern of normal and acquired mucosa-associated lymphoid tissue (MALT). The cytological features, growth pattern and IRTA1 positivity in nodal MZLs suggest they may derive from IRTA1(+) perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. Double immunostaining for IRTA1/bcl-6 tracked the colonization of B-cell follicles by MZL cells, and showed modulation of their phenotype (e.g. acquisition of bcl-6) during recirculation through germinal centres. MZL cells differentiating into plasma cells usually lost IRTA1. CONCLUSIONS: These results further expand our knowledge of the biology of MZLs, and highlight IRTA1 as the first positive marker for MZLs, enabling more accurate diagnosis of these neoplasms.
AIMS: The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas. METHODS AND RESULTS: Two thousand one hundred and four peripheral lymphomas of various types were immunostained with a monoclonal antibody against immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), which recognizes the equivalents of MZ in human lymphoid tissues other than spleen. IRTA1 expression was restricted to extranodal (93%) and nodal MZLs (73%) and to lymphomas with MZ differentiation. Extranodal MZL cells with the strongest IRTA1 expression were usually located adjacent to epithelia, mimicking the IRTA1 expression pattern of normal and acquired mucosa-associated lymphoid tissue (MALT). The cytological features, growth pattern and IRTA1 positivity in nodal MZLs suggest they may derive from IRTA1(+) perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. Double immunostaining for IRTA1/bcl-6 tracked the colonization of B-cell follicles by MZL cells, and showed modulation of their phenotype (e.g. acquisition of bcl-6) during recirculation through germinal centres. MZL cells differentiating into plasma cells usually lost IRTA1. CONCLUSIONS: These results further expand our knowledge of the biology of MZLs, and highlight IRTA1 as the first positive marker for MZLs, enabling more accurate diagnosis of these neoplasms.
Authors: Michiel van den Brand; Janneke J M Mathijssen; Mar Garcia-Garcia; Konnie M Hebeda; Patricia J T A Groenen; Brunangelo Falini; Sergio Serrano; J Han J M van Krieken Journal: Haematologica Date: 2015-06-11 Impact factor: 9.941
Authors: F J Li; W J Won; E J Becker; J L Easlick; E M Tabengwa; R Li; M Shakhmatov; K Honjo; P D Burrows; R S Davis Journal: Curr Top Microbiol Immunol Date: 2014 Impact factor: 4.291
Authors: Christina Kalpadakis; Gerassimos A Pangalis; Theodoros P Vassilakopoulos; Stavroula Kyriakaki; Xanthi Yiakoumis; Sotirios Sachanas; Maria Moschogiannis; Pantelis Tsirkinidis; Penelope Korkolopoulou; Helen A Papadaki; Maria K Angelopoulou Journal: Curr Hematol Malig Rep Date: 2014-09 Impact factor: 3.952
Authors: Jon Nicholas Rubenstein; Colleen Beatty; Zoe Kinkade; Cara Bryan; Jeffery Paul Hogg; Laura F Gibson; Jeffrey A Vos Journal: J Clin Exp Pathol Date: 2015-02-03